Weekly adalimumab improved symptoms in patients with moderate-to-severe disease.
Hidradenitis suppurativa (HS) can be a chronic, debilitating skin disorder. It is thought to be secondary to immunological or structural changes of hair follicles, and treatment options, including antibiotics, retinoids, and steroids, often fail to control skin lesions fully. In a 16-week, industry-sponsored, double-blind study, investigators randomly assigned 154 adults with moderate-to-severe HS to adalimumab (Humira; a tumor necrosis factor-? antagonist, which acts by suppressing the immune system) given weekly or every other week or to placebo.
